Equities research analysts expect Aerie Pharmaceuticals Inc (NASDAQ:AERI) to report ($1.01) earnings per share (EPS) for the current quarter, Zacks reports. Four analysts have provided estimates for Aerie Pharmaceuticals’ earnings. The lowest EPS estimate is ($1.10) and the highest is ($0.93). Aerie Pharmaceuticals reported earnings of ($1.38) per share during the same quarter last year, which would suggest a positive year over year growth rate of 26.8%. The business is expected to report its next earnings results on Wednesday, February 27th.
On average, analysts expect that Aerie Pharmaceuticals will report full-year earnings of ($4.71) per share for the current financial year, with EPS estimates ranging from ($4.84) to ($4.60). For the next financial year, analysts forecast that the firm will post earnings of ($2.39) per share, with EPS estimates ranging from ($3.35) to ($1.94). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that cover Aerie Pharmaceuticals.
Get Aerie Pharmaceuticals alerts:Aerie Pharmaceuticals (NASDAQ:AERI) last posted its earnings results on Tuesday, November 6th. The company reported ($1.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.40). The firm had revenue of $7.30 million for the quarter, compared to the consensus estimate of $5.63 million.
AERI has been the subject of a number of research analyst reports. BidaskClub upgraded shares of Aerie Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Monday, October 15th. ValuEngine cut shares of Aerie Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, January 2nd. Mizuho reiterated a “buy” rating and issued a $77.00 target price on shares of Aerie Pharmaceuticals in a research note on Wednesday, November 7th. Zacks Investment Research lowered shares of Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, January 15th. Finally, Oppenheimer started coverage on shares of Aerie Pharmaceuticals in a report on Monday, November 12th. They issued a “buy” rating and a $64.00 price target for the company. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $77.45.
In related news, insider Casey C. Kopczynski sold 11,000 shares of the firm’s stock in a transaction that occurred on Monday, December 3rd. The shares were sold at an average price of $39.81, for a total value of $437,910.00. Following the completion of the sale, the insider now owns 118,042 shares of the company’s stock, valued at $4,699,252.02. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Gerald D. Cagle purchased 2,000 shares of the stock in a transaction that occurred on Friday, November 16th. The stock was bought at an average cost of $41.75 per share, with a total value of $83,500.00. The disclosure for this purchase can be found here. In the last three months, insiders sold 33,000 shares of company stock valued at $1,333,090. 10.53% of the stock is currently owned by company insiders.
Several institutional investors have recently modified their holdings of AERI. BlackRock Inc. grew its holdings in Aerie Pharmaceuticals by 2.7% during the 4th quarter. BlackRock Inc. now owns 3,208,945 shares of the company’s stock worth $115,843,000 after acquiring an additional 84,605 shares during the period. Pearl River Capital LLC acquired a new stake in Aerie Pharmaceuticals during the 4th quarter worth $59,000. Prudential Financial Inc. grew its holdings in Aerie Pharmaceuticals by 40.9% during the 4th quarter. Prudential Financial Inc. now owns 157,961 shares of the company’s stock worth $5,613,000 after acquiring an additional 45,860 shares during the period. Essex Investment Management Co. LLC grew its holdings in Aerie Pharmaceuticals by 38.9% during the 4th quarter. Essex Investment Management Co. LLC now owns 93,578 shares of the company’s stock worth $3,378,000 after acquiring an additional 26,184 shares during the period. Finally, Rhenman & Partners Asset Management AB grew its holdings in Aerie Pharmaceuticals by 55.6% during the 4th quarter. Rhenman & Partners Asset Management AB now owns 280,000 shares of the company’s stock worth $10,108,000 after acquiring an additional 100,000 shares during the period.
Shares of NASDAQ:AERI traded down $2.68 during trading on Friday, reaching $40.39. The stock had a trading volume of 1,047,746 shares, compared to its average volume of 477,978. Aerie Pharmaceuticals has a 52 week low of $32.18 and a 52 week high of $74.75. The stock has a market capitalization of $1.96 billion, a P/E ratio of -11.99 and a beta of 1.10.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
See Also: Do back-end load funds outperform no-load funds?
Get a free copy of the Zacks research report on Aerie Pharmaceuticals (AERI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment